title: Randomized trial results of quality of life comparing whole abdominal irradiation and combination chemotherapy in advanced endometrial carcinoma: A gynecologic oncology group study.
abstract: OBJECTIVE
  To prospectively compare quality of life (QOL) outcomes in patients with advanced endometrial cancer treated with whole abdominal irradiation (WAI) or doxorubicin-cisplatin (AP) chemotherapy.
  
  
  METHODS
  Using the Fatigue Scale (FS), Assessment of Peripheral Neuropathy (APN), Functional Alterations due to Changes in Elimination (FACE), and Functional Assessment of Cancer Therapy-General (FACT-G), QOL was measured at: pre-treatment, end of treatment (EOT), and 3 and 6 months post-treatment.
  
  
  RESULTS
  317 of 396 eligible patients provided a baseline QOL assessment. The AP arm produced a statistically significant survival benefit along with greater toxicities, including peripheral neuropathy persisting up to 6 months. WAI patients reported worse FS (p < 0.001) and FACE (p < 0.001) scores at EOT and poorer FACE scores 3 months post-treatment (p = 0.004) compared to AP patients. APN scores were significantly worse among AP patients at EOT, and 3 and 6 months post-treatment (p < 0.001 for all). There is no indication that FACT-G scores differed between the two arms at any assessment point.
  
  
  CONCLUSIONS
  The trade-off for increased survival with AP is its potential for clinically significant peripheral neuropathy. This should be discussed with patients, particularly those who work with their hands or on their feet, in weighing therapeutic choices. Further research is needed to manage side effects having an enduring impact on QOL.
authors.affiliation: Department of Population Science and Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA. wbruner@nursing.upenn.edu
authors.forename: Deborah Watkins
authors.initials: DW
authors.lastname: Bruner
authors.forename: Andrea
authors.initials: A
authors.lastname: Barsevick
authors.forename: Chunqiao
authors.initials: C
authors.lastname: Tian
authors.forename: Marcus
authors.initials: M
authors.lastname: Randall
authors.forename: Robert
authors.initials: R
authors.lastname: Mannel
authors.forename: David E
authors.initials: DE
authors.lastname: Cohn
authors.forename: Joel
authors.initials: J
authors.lastname: Sorosky
authors.forename: Nick M
authors.initials: NM
authors.lastname: Spirtos
mesh_terms: D034841:Abdominal Cavity; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage; D016889:Endometrial Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D005260:Female; D006305:Health Status Indicators; D006801:Humans; D008875:Middle Aged; D010523:Peripheral Nervous System Diseases / Q000175:diagnosis; D011788:Quality of Life; D016896:Treatment Outcome
chemical_list: D004317:Doxorubicin; D002945:Cisplatin